Update on the treatments of non-alcoholic fatty liver disease (NAFLD)

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 9, Issue 4, 2009, Pages 261-270

  Quercioli, Alessandra ^a   Montecucco, Fabrizio ^b   Mach, François ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Cardiovascular risk; Metabolic syndrome; Non alcoholic fatty liver disease

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; BETAINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FOLIC ACID; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NATEGLINIDE; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; PROBIOTIC AGENT; PROBUCOL; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; URSODEOXYCHOLIC ACID; VSL3;

ABSENCE OF SIDE EFFECTS; ADIPOSE TISSUE; BARIATRIC SURGERY; BODY WEIGHT DISORDER; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FATTY LIVER; GASTROINTESTINAL SYMPTOM; HEPATITIS; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; LIPID STORAGE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MENTAL DISEASE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; VITAMIN SUPPLEMENTATION;

EID: 72449130087     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X10909040261     Document Type: Review

References (205)

1. Preiss, D.; Sattar, N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin. Sci. (Lond)., 2008, 115, 141-150.
2. Tarantino, G.; Conca, P.; Basile, V.; Gentile, A.; Capone, D.; Polichetti, G.; Leo, E. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol. Res., 2007, 37, 410-415. (Pubitemid 46915785)
3. Montecucco, F.; Mach, F. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk? Endocr. Metab. Immune. Disord. Drug Targets, 2008, 8, 301-307.
4. Bedogni, G.; Bellentani, S. Fatty liver: how frequent is it and why? Ann. Hepatol., 2004, 3, 63-65.
5. Ratziu, V.; Bugianesi, E.; Dixon, J.; Fassio, E.; Ekstedt, M.; Charlotte, F.; Kechagias, S.; Poynard, T.; Olsson, R. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment. Pharmacol. Ther., 2007, 26, 821-830. (Pubitemid 47346702)
6. Neuschwander-Tetri, B.A.; Caldwell, S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology, 2003, 37, 1202-1219.
7. Brunt, E.M. Nonalcoholic steatohepatitis. Semin. Liver Dis., 2004, 24, 3-20.
8. Oh, M.K.; Winn, J.; Poordad, F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther., 2008, 28, 503-522.
9. Bellentani, S.; Tiribelli, C.; Saccoccio, G.; Sodde, M.; Fratti, N.; De Martin, C.; Cristianini, G. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology, 1994, 20, 1442-1449. (Pubitemid 24359054)
10. Bellentani, S.; Saccoccio, G.; Masutti, F.; Crocè, L.S.; Brandi, G.; Sasso, F.; Cristanini, G.; Tiribelli, C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med., 2000, 132, 112-137. (Pubitemid 30044177)
11. Bedogni, G.; Miglioli, L.; Masutti, F.; Tiribelli, C.; Marchesini, G.; Bellentani, S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology, 2005, 42, 44-52. (Pubitemid 40911310)
12. Ruhl, C.E.; Everhart, J.E. Epidemiology of nonalcoholic fatty liver. Clin. Liver Dis., 2004, 8, 501-519. (Pubitemid 39141139)
13. Jimba, S.; Nakagami, T.; Takahashi, M.; Wakamatsu, T.; Hirota, Y.; Iwamoto, Y.; Wasada, T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med., 2005, 22, 1141-1145. (Pubitemid 41224170)
14. Browning, J.D.; Szczepaniak, L.S.; Dobbins, R.; Nurember, P.; Horton, J.D.; Cohen, J.C.; Grundy, S.M.; Hobbs, H.H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 2004, 40, 1387-1395.
15. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med., 2002, 346, 1221-1231. (Pubitemid 34984585)
16. Andersen, T.; Christoffersen, P.; Gluud, C. The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. Int. J. Obes., 1984, 8, 107-115. (Pubitemid 14130604)
17. Bacon, B.R.; Farahvash, M.J.; Janney, C.G.; Neuschwander-Tetri, B.A. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology, 1994, 107, 1103-1109.
18. Strauss, R.S.; Barlow, S.E.; Dietz, W.H. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J. Pediatr., 2000, 136, 727-1133
19. Schwimmer, J.B.; Deutsch, R.; Kahen, T.; Lavine, J.E.; Stanley, C.; Behling, C. Prevalence of fatty liver in children and adolescents. Pediatrics, 2006, 118, 1388-1393. (Pubitemid 46393782)
20. Tominaga, K.; Kurata, J.H.; Chen, Y.K.; Fujimoto, E.; Miyagawa, S.; Abe, I.; Kusano, Y. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig. Dis. Sci., 1995, 40, 2002-2009.
21. Sartorio, A.; Del Col, A.; Agosti, F.; Mazzilli, G.; Bellentani, S.; Tiribelli, C.; Bedogni, G. Predictors of non-alcoholic fatty liver disease in obese children. Eur. J. Clin. Nutr., 2007, 61, 877-883. (Pubitemid 47040311)
22. Baldridge, A.D.; Perez-Atayde, A.R.; Graeme-Cook, F.; Higgins, L.; Lavine, J.E. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J. Pediatr., 1995, 127, 700-704.
23. Schwimmer, J.B.; Deutsch, R.; Rauch, J.B.; Behling, C.; Newbury, R.; Lavine, J.E. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J. Pediatr., 2003; 143, 500-505. (Pubitemid 37352510)
24. Marchesini, G.; Brizi, M.; Morselli-Labate, A.M.; Bianchi, G.; Bugianesi, E.; McCullough, A.J.; Forlani, G.; Melchionda, N. As sociation of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med., 1999, 107, 450-455. (Pubitemid 29528333)
25. 25] Bugianesi, E.; McCullough, A.J.; Marchesini, G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology, 2005, 42, 987-1000. (Pubitemid 43112663)
26. 26] Boden, G.; She, P.; Mozzoli, M.; Cheung, P.; Gumireddy, K.; Reddy, P.; Xiang, X.; Luo, Z.; Ruderman, N. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes, 2005, 54, 3458-3465. (Pubitemid 43334336)
27. Kang, H.; Greenson, J.K.; Omo, J.T.; Chao, C.; Peterman, D.; Anderson, L.; Foess-Wood, L.; Sherbondy, M.A.; Conjeevaram, H.S. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am. J. Gastroenterol., 2006, 101, 2247-2253.
28. Chen, N.; Liu, L.; Zhang, Y.; Ginsberg, H.N.; Yu, Y.H. Wholebody insulin resistance in the absence of obesity in FVB mice with overexpression of Dgat1 in adipose tissue. Diabetes., 2005, 54, 3379-3386.
29. 29] Serviddio, G.; Sastre, J.; Bellanti, F.; Viña, J.; Vendemiale, G.; Altomare, E. Mitochondrial involvement in non-alcoholic steatohepatitis. Mol. Aspects Med., 2008, 29, 22-35. (Pubitemid 351312221)
30. Korenaga, M.; Okuda, M.; Otani, K.; Wang, T.; Li, Y.; Weinman, S.A. Mitochondrial dysfunction in hepatitis C. J. Clin. Gastroenterol., 2005, 39, S162-S166.
31. Cai, D.; Yuan, M.; Frantz, D.F.; Melendez, P.A.; Hansen, L.; Lee, J.; Shoelson, S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med., 2005, 11, 183-190.
32. 32] Crespo, J.; Cayón, A.; Fernández-Gil, P.; Hernández-Guerra, M.; Mayorga, M.; Domínguez-Díez, A.; Fernández-Escalante, J.C.; Pons-Romero, F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology, 2001, 34, 1158-1163. (Pubitemid 33096588)
33. Choudhury, J.; Sanyal, A.J. Insulin resistance in NASH. Front. Biosci., 2005, 10, 1520-1533.
34. Kern, P.A.; Saghizadeh, M.; Ong, J.M.; Bosch, R.J.; Deem, R.; Simsolo, R.B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest., 1995, 95, 2111-2119.
35. 35] Nishida, M.; Funahashi, T.; Shimomura, I. Pathophysiological significance of adiponectin. Med. Mol. Morphol., 2007, 40, 55-67. (Pubitemid 47305235)
36. Maeda, K.; Okubo, K.; Shimomura, I.; Funahashi, T.; Matsuzawa, Y.; Matsubara, K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun., 1996, 221, 286-289.
37. 37] Hui, J.M.; Hodge, A.; Farrell, G.C.; Kench, J.G.; Kriketos, A.; George, J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology, 2004, 40, 46-54. (Pubitemid 38868922)
38. Kaser, S.; Moschen, A.; Cayon, A.; Kaser, A.; Crespo, J.; Pons- Romero, F.; Ebenbichler, C.F.; Patsch, J.R.; Tilg, H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut, 2005, 54, 117-121.
39. Canbay, A.; Taimr, P.; Torok, N.; Higuchi, H.; Friedman, S.; Gores, G.J. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab. Invest., 2003, 83, 655-663
40. Fadok, V.A; Bratton, D.L.; Konowal, A.; Freed, P.W.; Westcott, J.Y.; Henson, P.M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest., 1998, 101, 890-898.
41. Leclercq, I.A.; Farrell, G.C.; Schriemer, R.; Robertson, G.R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol., 2002, 37, 206-213.
42. 42] Angulo, P.; Alba, L.M.; Petrovic, L.M.; Adams, L.A.; Lindor, K.D.; Jensen, M.D. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J. Hepatol., 2004, 41, 943-949. (Pubitemid 39575661)
43. Bataller, R.; Schwabe, R.F.; Choi, Y.H.; Yang, L.; Paik, Y.H.; Lindquist, J.; Qian, T.; Schoonhoven, R.; Hagedorn, C.H.; Lemasters, J.J.; Brenner, D.A. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest., 2003, 112, 1383-1394.
44. Oben, J.A.; Roskams, T.; Yang, S.; Lin, H.; Sinelli, N.; Li, Z.; Torbenson, M.; Thomas, S.A.; Diehl, A.M. Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice. Biochem. Biophys. Res. Commun., 2003, 308, 284-292.
45. Paradis, V.; Perlemuter, G.; Bonvoust, F.; Dargere, D.; Parfait, B.; Vidaud, M.; Conti, M.; Huet, S.; Ba, N.; Buffet, C.; Bedossa, P. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology, 2001, 34, 738-744. (Pubitemid 32927998)
46. Balaban, Y.H.; Sumer, H.; Simsek, H.; Us, D.; Tatar, G. Metabolic syndrome, non-alcoholic steatohepatitis (NASH), and hepatocyte growth factor (HGF). Ann. Hepatol., 2006, 5, 109-114. (Pubitemid 43876634)
47. Bahcecioglu, I.H.; Yalniz, M.; Ataseven, H.; Ilhan, N.; Ozercan, I.H.; Seckin, D.; Sahin, K. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology, 2005, 52, 1549-1553. (Pubitemid 41391035)
48. Mallat, A.; Lotersztajn, S. Endocannabinoids as novel mediators of liver diseases. J. Endocrinol. Invest., 2006, 29, 58-65.
49. Nomoto, K.; Tsuneyama, K.; Abdel Aziz, H.O.; Takahashi, H.; Murai, Y.; Cui, Z.G.; Fujimoto, M.; Kato, I.; Hiraga, K.; Hsu, D.K.; Liu, F.T.; Takano, Y. Disrupted galectin-3 causes nonalcoholic fatty liver disease in male mice. J. Pathol., 2006, 210, 469-477. (Pubitemid 44830607)
50. Malhi, H.; Bronk, S.F.; Werneburg, N.W.; Gores, G.J. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem., 2006, 281, 12093-12101.
51. Sattar, N.; Wannamethee, S.G.; Forouhi, N.G. Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia, 2008, 51, 926-940.
52. Pinto, H.C.; Baptista, A.; Camilo, M.E.; Valente, A.; Saragoça, A.; de Moura, M.C. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig. Dis. Sci., 1996, 41, 172-179. (Pubitemid 26064854)
53. Diehl, A. Nonalcoholic steatohepatitis. Semin. Liver Dis., 1999, 19, 221-229.
54. Ramesh, S.; Sanyal, A.J. Evaluation and management of nonalcoholic steatohepatitis. J. Hepatol., 2005, 42, S2-12.
55. Angulo, P.; Keach, J.C.; Batts, K.P.; Lindor, K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology, 1999, 30, 1356-1362.
56. Brunt, E.M.; Tiniakos, D.G. Pathology of steatohepatitis. Best. Pract. Res. Clin. Gastroenterol., 2002, 16, 691-707.
57. Adams, L.A.; Angulo, P. Recent concepts in non-alcoholic fatty liver disease. Diabet. Med., 2005, 22, 1129-1133. (Pubitemid 41224168)
58. Ekstedt, M.; Franzen, L.E.; Mathiesen, U.L.; Thorelius, L.; Holmqvist, M.; Bodemar, G.; Kechagias, S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 2006, 44, 865-873. (Pubitemid 46489550)
59. Rafiq, N.; Bai, C.; Fang, Y.; Srishord, M.; McCullough, A.; Gramlich, T.; Younossi, Z.M. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol., 2009, 7, 234-238.
60. Bugianesi, E. Nonalcoholic fatty liver disease (NAFLD) and cardiac lipotoxicity: Another piece of the puzzle. Hepatology, 2008, 47, 2-4. (Pubitemid 351171032)
61. Adams, L.A.; Lymp, J.F.; St Sauver, J.; Sanderson, S.O.; Lindor, K.D.; Feldstein, A.; Angulo, P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology, 2005, 129, 113-121. (Pubitemid 41002048)
62. Ong, J.P.; Pitts, A.; Younossi, Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol., 2008, 49, 608-612.
63. Schindhelm, R.K.; Diamant, M.; Dekker, J.M.; Tushuizen, M.E.; Teerlink, T.; Heine, R.J. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab. Res. Rev., 2006, 22, 437-443.
64. Schindhelm, R.K.; Dekker, J.M.; Nijpels, G.; Bouter, L.M.; Stehouwer, C.D.; Heine, R.J.; Diamant, M. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis, 2007, 191, 391-396. (Pubitemid 46400701)
65. Targher, G.; Bertolini, L.; Rodella, S.; Lippi, G.; Franchini, M.; Zoppini, G.; Muggeo, M.; Day, C.P. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring), 2008, 16, 1394-1399.
66. Vuppalanchi, R.; Chalasani, N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology, 2009, 49, 306-317.
67. Andersen, T.; Gluud, C.; Franzmann, M.B.; Christoffersen, P. Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol., 1991, 12, 224-229.
68. Torres, D.M.; Harrison, S.A. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology, 2008, 134, 1682-1698.
69. Huang, M.A.; Greenson, J.K.; Chao, C.; Anderson, L.; Peterman, D.; Jacobson, J.; Emick, D.; Lok, A.S.; Conjeevaram, H.S. Oneyear intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am. J. Gastroenterol., 2005, 100, 1072-1081.
70. Younossi, Z.M. Review article: current management of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther., 2008, 28, 2-12.
71. Wang, C.L.; Liang, L.; Fu, J.F.; Zou, C.C.; Hong, F.; Xue, J.Z.; Lu, J.R.; Wu, X.M. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J. Gastroenterol., 2008, 14, 1598-1602.
72. Reinehr, T.; Schmidt, C.; Andler, W.; Toschke, A.M.. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: two years follow-up study. Arch. Dis. Child., 2009, 94, 437-442.
73. Sabuncu, T.; Nazligul, Y.; Karaoglanoglu, M.; Ucar, E.; Kilic, F.B. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom. J. Gastroenterol., 2003, 12, 189-192.
74. Harrison, S.A.; Fecht, W.; Brunt, E.M.; Neuschwander-Tetri, B.A. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology, 2009, 49, 80-86.
75. Brolin, R. Bariatric surgery and long-term control of morbid obesity. JAMA, 2002, 288, 2793-2796. (Pubitemid 35425059)
76. Di Marzo, V.; Matias, I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci., 2005, 8, 585-589. (Pubitemid 40594198)
77. Osei-Hyiaman, D.; DePetrillo, M.; Pacher, P.; Liu, J.; Radaeva, S.; Bátkai, S.; Harvey-White, J.; Mackie, K.; Offertáler, L.; Wang, L.; Kunos, G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest., 2005, 115, 1298-1305. (Pubitemid 40629049)
78. Mallat, A.; Teixeira-Clerc, F.; Deveaux, V.; Lotersztajn, S. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin. Ther. Targets, 2007, 11, 403-409. (Pubitemid 46290962)
79. Vemuri, V.K.; Janero, D.R.; Makriyannis, A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol. Behav., 2008, 93, 671-686.
80. Van Gaal, L.F.; Rissanen, A.M.; Scheen, A.J.; Ziegler, O.; Rössner, S.; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 2005, 365, 1389-1397. (Pubitemid 40523733)
81. Pi-Sunyer, F.X.; Aronne, L.J.; Heshmati, H.M.; Devin, J.; Rosenstock, J. RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA, 2006, 295, 761-775.
82. Teixeira-Clerc, F.; Julien, B.; Grenard, P.; Tran Van Nhieu, J.; Deveaux, V.; Li, L.; Serriere-Lanneau, V.; Ledent, C.; Mallat, A.; Lotersztajn, S. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med., 2006, 12, 671-676. (Pubitemid 43865236)
83. Gary-Bobo, M.; Elachouri, G.; Gallas, J.F.; Janiak, P.; Marini, P.; Ravinet-Trillou, C.; Chabbert, M.; Cruccioli, N.; Pfersdorff, C.; Roque, C.; Arnone, M.; Croci, T.; Soubrié, P.; Oury-Donat, F.; Maffrand, J.P.; Scatton, B.; Lacheretz, F.; Le Fur, G.; Herbert, J.M.; Bensaid. M. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology, 2007, 46, 122-129. (Pubitemid 47171928)
84. 84] Levy, P.; Fried, M.; Santini, F.; Finer, N. The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes. Surg., 2007, 17, 1248-1256. (Pubitemid 351321338)
85. Sears, D.; Fillmore, G.; Bui, M.; Rodriguez, J. Evaluation of gastric bypass patients 1 year after surgery: changes in quality of life and obesity-related conditions. Obes. Surg., 2008, 18, 1522-1525.
86. 86] Sjöström, L.; Lindroos, A.K.; Peltonen, M.; Torgerson, J.; Bouchard, C.; Carlsson, B.; Dahlgren, S.; Larsson, B.; Narbro, K.; Sjöström, C.D.; Sullivan, M.; Wedel, H.; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med., 2004, 351, 2683-2693. (Pubitemid 39665322)
87. Mummadi, R.R.; Kasturi, K.S.; Chennareddygari, S.; Sood, G.K. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol., 2008, 6, 1396-1402.
88. Cubero, F.J.; Nieto, N. Ethanol and arachidonic acid synergize to activate Kupffer cells and modulate the fibrogenic response via tumor necrosis factor alpha, reduced glutathione, and transforming growth factor beta-dependent mechanisms. Hepatology, 2008, 48, 2027-2039.
89. 89] Hasegawa, T.; Yoneda, M.; Nakamura, K.; Makino, I.; Terano, A. Plasma transforming growth factor-beta1 level and efficacy of alpha- tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment. Pharmacol. Ther., 2001, 15, 1667-1672 (Pubitemid 32912411)
90. 90] Lavine, J. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J. Pediatr., 2000, 136, 734-738. (Pubitemid 30415645)
91. Kugelmas, M.; Hill, D.B.; Vivian, B.; Marsano, L.; McClain, C.J. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology, 2003, 38, 413-419.
92. Sanyal, A.J.; Mofrad, P.S.; Contos, M.J.; Sargeant, C.; Luketic, V.A.; Sterling, R.K.; Stravitz, R.T.; Shiffman, M.L.; Clore, J.; Mills, A.S. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol., 2004, 2, 1107-1115.
93. 93] Bugianesi, E.; Gentilcore, E.; Manini, R.; Natale, S.; Vanni, E.; Villanova, N.; David, E.; Rizzetto, M.; Marchesini, G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol., 2005, 100, 1082-1090. (Pubitemid 40769045)
94. 94] Vajro, P.; Mandato, C.; Franzese, A.; Ciccimarra, E.; Lucariello, S.; Savoia, M.; Capuano, G.; Migliaro, F. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J. Pediatr. Gastroenterol. Nutr., 2004, 38, 48-55. (Pubitemid 39274467)
95. Harrison, S.A.; Torgerson, S.; Hayashi, P.; Ward, J.; Schenker, S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2003, 98, 2485-2490.
96. Miller, E.R.; Pastor-Barriuso, R.; Dalal, D.; Riemersma, R.A.; Appel, L.J.; Guallar, E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med., 2005, 142, 137-146.
97. Chalasani, N.P.; Sanyal, A.J.; Kowdley, K.V.; Robuck, P.R.; Hoofnagle, J.; Kleiner, D.E.; Unalp, A.; Tonascia, J. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp. Clin. Trials., 2009, 30, 88-96.
98. 98] Mehta, K.; Van Thiel, D.H.; Shah, N.; Mobarhan, S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr. Rev., 2002, 60, 289-293. (Pubitemid 35025794)
99. 99] Abdelmalek, M.F.; Angulo, P.; Jorgensen, R.A.; Sylvestre, P.B.; Lindor, K.D. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol., 2001, 96, 2711-2717. (Pubitemid 32889210)
100. Kim, H.Y.; Gladyshev, V.N. Methionine sulfoxide reductases: selenoprotein forms and roles in antioxidant protein repair in mammals. Biochem. J., 2007, 407, 321-329.
101. 101] Neuner, P.; Klosner, G.; Schauer, E.; Pourmojib, M.; Macheiner, W.; Grünwald, C.; Knobler, R.; Schwarz, A.; Luger, T.A.; Schwarz, T. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology, 1994, 83, 262-267. (Pubitemid 24315597)
102. Satapathy, S.K.; Garg, S.; Chauhan, R.; Sakhuja, P.; Malhotra, V.; Sharma, B.C.; Sarin, SK. Beneficial effects of tumor necrosis factor- alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2004, 99, 1946-1952.
103. 103] Adams, L.A.; Zein, C.O.; Angulo, P.; Lindor, K.D. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol., 2004, 99, 2365-2368. (Pubitemid 40039367)
104. Satapathy, S.K.; Sakhuja, P.; Malhotra, V.; Sharma, B.C.; Sarin, S.K. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol., 2007, 22, 634-638.
105. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M.F.; Goodyear, L.J.; Moller, D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 2001, 108, 1167-1174.
106. 106] Kral, J.G.; Thung, S.N.; Biron, S.; Hould, F.S.; Lebel, S; Marceau, S.; Simard, S.; Marceau, P. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery, 2004, 135, 48-58. (Pubitemid 38041453)
107. Kirpichnikov, D.; McFarlane, S.I.; Sowers, J.R. Metformin: an update. Ann. Intern. Med., 2002, 137, 25-33.
108. Marchesini, G.; Brizi, M.; Bianchi, G.; Tomassetti, S.; Zoli, M.; Melchionda, N. Metformin in non-alcoholic steatohepatitis. Lancet, 2001, 358, 893-894.
109. 109] Hattori, Y.; Suzuki, K.; Hattori, S.; Kasai, K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension, 2006, 47, 1183-1188. (Pubitemid 44289177)
110. Lin, H.Z.; Yang, S.Q.; Chuckaree, C.; Kuhajda, F.; Ronnet, G.; Diehl, A.M. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat. Med. 2000, 6, 998-1003.
111. 111] Bugianesi, E.; Gentilcore, E.; Manini, R.; Natale, S.; Vanni, E.; Villanova, N.; David, E.; Rizzetto, M.; Marchesini, G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol., 2005, 100, 1082-1090. (Pubitemid 40769045)
112. 112] Uygun, A.; Kadayifci, A.; Isik, A.T.; Ozgurtas, T.; Deveci, S.; Tuzun, A.; Yesilova, Z.; Gulsen, M.; Dagalp, K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther., 2004, 19, 537-544. (Pubitemid 38387180)
113. Duseja, A.; Das, A.; Dhiman, R.K.; Chawla, Y.K.; Thumburu, K.T.; Bhadada, S.; Bhansali, A. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann. Hepatol., 2007, 6, 222-226.
114. Nair, S.; Diehl, A.M.; Wiseman, M.; Farr, G.H. Jr; Perrillo, R.P. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment. Pharmacol. Ther., 2004, 20, 23-28.
115. Nar, A.; Gedik, O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol., 2009, 46, 113-118.
116. Duseja, A.; Das, A.; Dhiman, R.K.; Chawla, Y.K.; Thumburu, K.T.; Bhadada, S.; Bhansali, A. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann. Hepatol., 2007, 6, 222-226.
117. Nadeau, K.J.; Ehlers, L.B.; Zeitler, P.S.; Love-Osborne, K. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr. Diabetes, 2009, 10, 5-13.
118. Raso, G.M.; Esposito, E.; Iacono, A.; Pacilio, M.; Cuzzocrea, S.; Canani, R.B.; Calignano, A.; Meli, R. Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat. Eur. J. Pharmacol., 2009, 604, 125-131.
119. Yki-Jarvinen, H. Thiazolidinediones. N. Engl. J. Med., 2004, 351, 1106-1118.
120. Girard, J. Mechanisms of action of thiazolidinediones. Diabetes Metab., 2001, 27, 271-278.
121. Riera-Guardia, N.; Rothenbacher, D. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes. Metab., 2008, 10, 367-375.
122. Shulman, G. Cellular mechanisms of insulin resistance. J. Clin. Invest., 2000, 106, 171-176. (Pubitemid 30483118)
123. Mohanty, P.; Aljada, A.; Ghanim, H.; Hofmeyer, D.; Tripathy, D.; Syed, T.; Al-Haddad, W.; Dhindsa, S.; Dandona, P. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab., 2004, 89, 2728-2735.
124. Lutchman, G.; Promrat, K.; Kleiner, D.E.; Heller, T.; Ghany, M.G.; Yanovski, J.A.; Liang, T.J.; Hoofnagle, J.H. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin. Gastroenterol. Hepatol., 2006, 4, 1048-1052.
125. Neuschwander-Tetri, B.A.; Brunt, E.M.; Wehmeier, K.R.; Oliver, D.; Bacon, B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology, 2003, 38, 1008-1017.
126. Promrat, K.; Lutchman, G.; Uwaifo, G.I.; Freedman, R.J.; Soza, A.; Heller, T.; Doo, E.; Ghany, M.; Premkumar, A.; Park, Y.; Liang, T.J.; Yanovski, J.A.; Kleiner, D.; Hoofnagle, J.H. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 2004, 39, 188-196. (Pubitemid 38461481)
127. Belfort, R.; Harrison, S.A.; Brown, K.; Darland, C.; Finch, J.; Hardies, J.; Balas, B.; Gastaldelli, A.; Tio, F.; Pulcini, J.; Berria, R.; Ma, J.Z.; Dwivedi, S.; Havranek, R.; Fincke, C.; DeFronzo, R.; Bannayan, G.A.; Schenker, S.; Cusi, K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med., 2006, 355, 2297-2307. (Pubitemid 44837778)
128. Akyuz, F.; Demir, K.; Ozdil, S.; Aksoy, N.; Poturoglu, S.; Ibrisim, D.; Kaymakoglu, S.; Besisik, F.; Boztas, G.; Cakaloglu, Y.; Mungan, Z.; Cevikbas, U.; Okten, A. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig. Dis. Sci., 2007, 52, 2359-2367. (Pubitemid 47246475)
129. Hsiao, P.J.; Hsieh, T.J.; Kuo, K.K.; Hung, W.W.; Tsai, K.B.; Yang, C.H.; Yu, M.L.; Shin, S.J. Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet. BMC Mol. Biol., 2008, 9, 82.
130. Ratziu, V.; Giral, P.; Jacqueminet, S.; Charlotte, F.; Hartemann- Heurtier, A.; Serfaty, L.; Podevin, P.; Lacorte, J.M.; Bernhardt, C.; Bruckert, E.; Grimaldi, A.; Poynard, T. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology, 2008, 135, 100-110. (Pubitemid 351916703)
131. Lutchman, G.; Modi, A.; Kleiner, D.E.; Promrat, K.; Heller, T.; Ghany, M.; Borg, B.; Loomba, R.; Liang, T.J.; Premkumar, A.; Hoofnagle, J.H: The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology, 2007, 46, 424-429. (Pubitemid 47344777)
132. Assy, N.; Grozovski, M.; Bersudsky, I.; Szvalb, S.; Hussein, O. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J. Gastroenterol., 2006, 12, 4369-4376. (Pubitemid 44194531)
133. Aithal, G.P.; Thomas, J.A.; Kaye, P.V.; Lawson, A.; Ryder, S.D.; Spendlove, I.; Austin, A.S.; Freeman, J.G.; Morgan, L.; Webber, J: Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 2008, 135, 1176-1184.
134. Doyle, M.E.; Egan, J.M. Pharmacological agents that directly modulate insulin secretion. Pharmacol. Rev., 2003, 55, 105-131.
135. Ding, X.; Saxena, N.K.; Lin, S.; Gupta, N.A.; Anania, F.A. Exendin- 4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology, 2006, 43, 173-181.
136. Morita, Y.; Ueno, T.; Sasaki, N.; Tateishi, Y.; Nagata, E.; Kage, M.; Sata, M. Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. Hepatogastroenterology, 2005, 52, 1338-1343. (Pubitemid 41390988)
137. Barter, P.; Ginsberg, H.N. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am. J. Cardiol., 2008, 102, 1040-1045.
138. Gomez-Dominguez, E.; Gisbert, J.P.; Moreno-Monteagudo, J.A.; Garcia-Buey, L.; Moreno-Otero, R: A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment. Pharmacol. Ther., 2006, 23, 1643-1647.
139. Ekstedt, M.; Franzen, L.E.; Mathiesen, U.L.; Holmqvist, M.; Bodemar, G.; Kechagias, S: Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J. Hepatol., 2007, 47, 135-141.
140. Kiyici, M.; Gulten, M.; Gurel, S.; Nak, S.G.; Dolar, E.; Savci, G.; Adim, S.B.; Yerci, O.; Memik, F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol., 2003, 17, 713-718. (Pubitemid 38072335)
141. Rallidis, L.S.; Drakoulis, C.K.; Parasi, A.S. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis, 2004, 174, 193-196. (Pubitemid 38595458)
142. Chalasani, N.; Aljadhey, H.; Kesterson, J.; Murray, M.D.; Hall, S.D. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology, 2004, 126, 1287-1292.
143. Barter, P.J.; Rye, K.A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler. Thromb. Vasc. Biol., 2008, 28, 39-46.
144. Fernández-Miranda, C.; Pérez-Carreras, M.; Colina, F.; López- Alonso, G.; Vargas, C.; Solís-Herruzo, J.A. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig. Liver. Dis., 2008, 40, 200-205. (Pubitemid 351181792)
145. Laurin, J.; Lindor, K.D.; Crippin, J.S.; Gossard, A.; Gores, G.J.;
146. Basaranoglu, M.; Acbay, O.; Sonsuz, A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J. Hepatol., 1999, 31, 384. (Pubitemid 29349772)
147. Merat, S,;Aduli, M.; Kazemi, R.; Sotoudeh, M.; Sedighi, N.; Sohrabi, M.; Malekzadeh, R. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig. Dis. Sci., 2008, 53, 2246-2250.
148. Tanaka, N.; Sano, K.; Horiuchi, A.; Tanaka, E.; Kiyosawa, K.; Aoyama, T: Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol., 2008, 42, 413-418.
149. Elizondo, A.; Araya, J.; Rodrigo, R.; Signorini, C.; Sgherri, C.; Comporti, M.; Poniachik, J.; Videla, L.A. Effects of weight loss on liver and erythrocyte polyunsaturated fatty acid pattern and oxidative stress status in obese patients with non-alcoholic fatty liver disease. Biol. Res., 2008, 41, 59-68.
150. Cope, K.; Risby, T.; Diehl, A.M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology, 2000, 119, 1340-1347.
151. Li, Z.; Yang, S.; Lin, H.; Huang, J.; Watkins, P.A.; Moser, A.B.; Desimone, C.; Song, X.Y.; Diehl, A.M. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology, 2003, 37, 343-350.
152. Loguercio, C.; Federico, A.; Tuccillo, C.; Terracciano, F.; D'Auria, M.V.; De Simone, C.; Del Vecchio Blanco, C: Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol., 2005, 39, 540-543.
153. Velayudham, A.; Dolganiuc, A.; Ellis, M.; Petrasek, J.; Kodys, K.; Mandrekar, P.; Szabo, G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology, 2009, 49, 989-997.
154. Lindor, K.D.; Kowdley, K.V.; Heathcote, E.J.; Harrison, M.E.; Jorgensen, R.; Angulo, P.; Lymp, J.F.; Burgart, L.; Colin, P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology, 2004, 39, 770-778. (Pubitemid 38337657)
155. Moreira, R. Hepatic stellate cells and liver fibrosis. Arch. Pathol. Lab. Med., 2007, 131, 1728-1734.
156. Hirose, A.; Ono, M.; Saibara, T.; Nozaki, Y.; Masuda, K.; Yoshioka, A.; Takahashi, M.; Akisawa, N.; Iwasaki, S.; Oben, J.A.; Onishi, S. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology, 2007, 45, 1375-1381. (Pubitemid 46918321)
157. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Nakatani, T.; Tsujinoue, H.; Fukui, H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology, 2001, 34, 745-750. (Pubitemid 32927999)
158. Yang, L.; Bataller, R.; Dulyx, J.; Coffman, T.M.; Ginès, P.; Rippe, R.A.; Brenner, D.A. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J. Hepatol., 2005, 43, 317-323. (Pubitemid 40956886)
159. Enjoji, M.; Kotoh, K.; Kato, M.; Higuchi, N.; Kohjima, M.; Nakashima, M.; Nakamuta, M. Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study. Int. J. Mol. Med., 2008, 22, 521-527.
160. Yokohama, S.; Yoneda, M.; Haneda, M.; Okamoto, S.; Okada, M.; Aso, K.; Hasegawa, T.; Tokusashi, Y.; Miyokawa, N.; Nakamura, K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology, 2004, 40, 1222-1225. (Pubitemid 39425579)
161. Kok, N.; Roberfroid, M.; Robert, A.; Delzenne, N. Involvement of lipogenesis in the lower VLDL secretion induced by oligofructose in rats. Br. J. Nutr., 1996, 76, 881-890. (Pubitemid 27029128)
162. Daubioul, C.A.; Taper, H.S.; De Wispelaere, L.D.; Delzenne, N.M. Dietary oligofructose lessens hepatic steatosis, but does not prevent hypertriglyceridemia in obese zucker rats. J. Nutr., 2000, 130, 1314-1319.
163. Charatcharoenwitthaya, P.; Levy, C.; Angulo, P.; Keach, J.; Jorgensen, R.; Lindor, K.D. Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int., 2007, 27, 220-226. (Pubitemid 46680726)
164. Spiegelman, B.M.; Flier, J.S. Obesity and the regulation of energy balance. Cell, 2001, 104, 531-1143
165. Friedman, J.M.; Halaas, J.L. Leptin and the regulation of body weight in mammals. Nature, 1998, 395, 6763-6770.
166. Hotamisligil, G.S.; Spiegelman, B.M. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes, 1994, 43, 1271-1278.
167. Agheli, N.; Kabir, M.; Berni-Canani, S.; Petitjean, E.; Boussairi, A.; Luo, J.; Bornet, F.; Slama, G.; Rizkalla, S.W. Plasma lipids and fatty acid synthase activity are regulated by short-chain fructooligosaccharides in sucrose-fed insulin-resistant rats. J. Nutr., 1998, 128, 1283-1288.
168. Saxena, N.K.; Titus, M.A.; Ding, X.; Floyd, J.; Srinivasan, S.; Sitaraman, S.V.; Anania, F.A. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J., 2004, 18, 1612-1614.
169. Aleffi, S., Petrai, I.; Bertolani, C.; Parola, M.; Colombatto, S.; Novo, E.; Vizzutti, F.; Anania, F.A.; Milani, S.; Rombouts, K.; Laffi, G.; Pinzani, M.; Marra, F. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology, 2005, 42, 1339-1348. (Pubitemid 43260036)
170. Honda, H.; Ikejima, K.; Hirose, M.; Yoshikawa, M.; Lang, T.; Enomoto, N.; Kitamura, T.; Takei, Y.; Sato, N. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology, 2002, 36, 12-21. (Pubitemid 34700757)
171. Leclercq, I.A.; Farrell, G.C.; Schriemer, R.; Robertson, G.R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol., 2002, 37, 206-213.
172. Saxena, N.K.; Ikeda, K.; Rockey, D.C.; Friedman, S.L.; Anania, F.A. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology, 2002, 35, 762-771.
173. Ikejima, K.; Takei, Y.; Honda, H.; Hirose, M.; Yoshikawa, M.; Zhang, Y.J.; Lang, T.; Fukuda, T.; Yamashina, S.; Kitamura, T.; Sato, N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology, 2002, 122, 1399-1410. (Pubitemid 34465182)
174. Ikejima, K.; Honda, H.; Yoshikawa, M.; Hirose, M.; Kitamura, T.; Takei, Y.; Sato, N. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology, 2001, 34, 288-297. (Pubitemid 32702342)
175. Halaas, J.L.; Friedman, J.M. Leptin and its receptor. J. Endocrinol., 1997, 155, 215-1156
176. Zhang, Y.; Proenca, R.; Maffei, M.; Barone, M.; Leopold, L.; Friedman, J.M. Positional cloning of the mouse obese gene and its human homologue. Nature, 1994, 372, 6425-6532.
177. Kamada, Y.; Takehara, T.; Hayashi, N. Adipocytokines and liver disease. J. Gastroenterol., 2008, 43, 811-822.
178. Cao, Q,; Mak, K.M.; Ren, C.; Lieber, C.S. Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells: respective roles of the JAK/STAT and JAK-mediated H2O2-dependant MAPK pathways. J. Biol. Chem., 2004, 279, 4292-4304.
179. Cao, Q.; Mak, K.M.; Lieber, C.S. Leptin enhances alpha1(I) collagen gene expression in LX-2 human hepatic stellate cells through JAK-mediated H2O2-dependent MAPK pathways. J. Cell Biochem., 2006, 97, 188-197.
180. Qamar, A.; Sheikh, S.Z.; Masud, A.; Jhandier, M.N.; Inayat, I.B.; Hakim, W.; Mehal, W.Z. In vitro and in vivo protection of stellate cells from apoptosis by leptin. Dig. Dis. Sci., 2006, 51, 1697-1705.
181. Elinav, E.; Ali, M.; Bruck, R.; Brazowski, E.; Phillips, A.; Shapira, Y.; Katz, M.; Solomon, G.; Halpern, Z.; Gertler, A. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology, 2009, 49, 278-286.
182. Galli, A.; Crabb, D.; Price, D.; Ceni, E.; Salzano, R.; Surrenti, C.; Casini, A. Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factorinduced proliferation of human hepatic stellate cells. Hepatology, 2000, 31, 101-108. (Pubitemid 30033695)
183. Marra, F.; Efsen, E.; Romanelli, R.G.; Caligiuri, A.; Pastacaldi, S.; Batignani, G.; Bonacchi, A.; Caporale, R.; Laffi, G.; Pinzani, M.; Gentilini, P. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology, 2000, 119, 466-478. (Pubitemid 30621997)
184. Miyahara, T.; Schrum, L.; Rippe, R.; Xiong, S.; Yee, H.F.Jr.; Motomura, K.; Anania, F.A.; Willson, T.M.; Tsukamoto, H. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J. Biol. Chem., 2000, 275, 35715-35722. (Pubitemid 30841104)
185. Hazra, S.; Xiong, S.; Wang, J.; Rippe, R.A.; Krishna, V.; Chatterjee, K.; Tsukamoto, H. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J. Biol. Chem., 2004, 279, 11392-11401. (Pubitemid 38401638)
186. Zhou, Y.; Jia, X.; Wang, G.; Wang, X.; Liu, J. PI-3 K/AKT and ERK signaling pathways mediate leptin-induced inhibition of PPARgamma gene expression in primary rat hepatic stellate cells. Mol. Cell Biochem., 2009, 325, 131-139.
187. Xiong, F.L.; Sun, X.H.; Gan, L.; Yang, X.L.; Xu, H.B. Puerarin protects rat pancreatic islets from damage by hydrogen peroxide. Eur. J. Pharmacol., 2006, 529, 1-7.
188. Kapiotis, S.; Hermann, M.; Held, I.; Seelos, C.; Ehringer, H.; Gmeiner, B.M. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 2868-2874.
189. Yen, G.C.; Lai, H.H. Inhibitory effects of isoflavones on nitric oxide- or peroxynitrite-mediated DNA damage in RAW 264.7 cells and phiX174 DNA. Food Chem. Toxicol., 2002, 40, 1433-1440.
190. Vedavanam, K.; Srijayanta, S.; O'Reilly, J.; Raman, A.; Wiseman, H. Antioxidant action and potential antidiabetic properties of an isoflavonoid-containing soyabean phytochemical extract (SPE). Phytother. Res., 1999, 13, 601-608. (Pubitemid 29520939)
191. Chung, M.J.; Sung, N.J.; Park, C.S.; Kweon, D.K.; Mantovani, A.; Moon, T.W.; Lee, S.J.; Park, K.H. Antioxidative and hypocholesterolemic activities of water-soluble puerarin glycosides in HepG2 cells and in C57 BL/6J mice. Eur. J. Pharmacol.; 2008, 578, 159-170
192. Zheng, P.Y.; Ma, Z.S.; Hua, Y.Q.; Liu, T.; Xing, L.J.; Ji, G. Effects of puerarin on expressions of leptin receptor mRNA, phosphorylated Janus kinase 2/phosphorylated signal transducers and activators of transcription 3 proteins in the liver of rats with nonalcoholic fatty liver. Zhong. Xi. Yi. Jie. He. Xue. Bao., 2008, 6, 921-927.
193. Zheng, P.; Ji, G.; Ma, Z.; Liu, T.; Xin, L.; Wu, H.; Liang, X.; Liu, J. Therapeutic Effect of Puerarin on Non-Alcoholic Rat Fatty Liver by Improving Leptin Signal Transduction through JAK2/STAT3 Pathways. Am. J. Chin. Med., 2009, 37, 69-83.
194. Altmann, S.W.; Davis, H.R.Jr.; Zhu, L.J.; Yao, X.; Hoos, L.M.; Tetzloff, G.; Iyer, S.P.; Maguire, M.; Golovko, A.; Zeng, M.; Wang, L.; Murgolo, N.; Graziano, M.P. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 2004, 303, 1201-1204.
195. Yamagishi, S.; Nakamura, K.; Matsui, T.; Sato, T.; Takeuchi, M. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Med. Hypotheses, 2006, 66, 844-846. (Pubitemid 43181635)
196. Zheng, S.; Hoos, L.; Cook, J.; Tetzloff, G.; Davis, H,Jr.; van Heek, M.; Hwa, J.J: Ezetimibe improves high fat and cholesterol dietinduced non-alcoholic fatty liver disease in mice. Eur. J. Pharmacol., 2008, 584, 118-124.
197. Jull, A.B.; Ni Mhurchu, C.; Bennett, D.A.; Dunshea-Mooij, C.A.; Rodgers, A. Chitosan for overweight or obesity. Cochrane Database Syst. Rev., 2008, (13), CD003892.
198. Zhang, J.; Liu, J.; Li, L.; Xia, W. Dietary chitosan improves hypercholesterolemia in rats fed high-fat diets. Nutr. Res., 2008, 28, 383-390. (Pubitemid 351718471)
199. Vahouny, G.V.; Satchithanandam, S.; Cassidy, M.M.; Lightfoot, F.B.; Furda, I. Comparative effects of chitosan and cholestyramine on lymphatic absorption of lipids in the rat. Am. J. Clin. Nutr., 1983, 38, 278-284.
200. Kanauchi, O.; Deuchi, K.; Imasato, Y.; Shizukuishi, M.; Kobayashi, E. Mechanism for the inhibition of fat digestion by chitosan and for the synergistic effect of ascorbate. Biosci. Biotechnol. Biochem., 1995, 59, 786-790.
201. LeHoux, J.G.; Grondin, F. Some effects of chitosan on liver function in the rat. Endocrinology, 1993, 132, 1078-1084. (Pubitemid 23068621)
202. Zhou, G.D.; Li, M.R.; Zhang, J.; Pan, D.; Zhao, S.X.; Yang, J.F.; Yu, J.; Zhao, J.M. Chitosan ameliorates the severity of steatohepatitis induced by high fat diet in rats. Scand. J. Gastroenterol., 2008, 43, 1371-1377.
203. Park, S.Y.; Shin, H.K.; Lee, J.H.; Kim, C.D.; Lee, W.S.; Rhim, B.Y.; Hong, K.W. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in db/db Mouse model of Type 2 diabetes via activation of peroxisome proliferator-activated receptor {gamma} transcription. J. Pharmacol. Exp. Ther., 2009, 329, 571-579.
204. Fujita, K.; Nozaki, Y.; Wada, K.; Yoneda, M.; Endo, H.; Takahashi, H.; Iwasaki, T.; Inamori, M.; Abe, Y.; Kobayashi, N.; Kirikoshi, H.; Kubota, K.; Saito, S.; Nagashima, Y.; Nakajima, A. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut., 2008, 57, 1583-1591.
205. Kwon do, Y.; Jung, Y.S.; Kim, S.J.; Park, H.K.; Park, J.H.; Kim, Y.C. Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J. Nutr., 2009, 139, 163-1138